ARMISTICE CAPITAL, LLC
Q2 2024 13F-HR Holdings
Net value change ($000)
+407,335
(5.4%)
New positions
77
Sold out positions
156
Turnover %
18.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2024
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ALKERMES PLC | 46,853 | 257.5% |
| Inari Medical, Inc. | 37,907 | 354.7% |
| SMPL | 34,582 | NEW |
| KDP | 33,713 | 211.7% |
| NVO | 26,291 | 51.2% |
| PENN | 26,080 | 104.0% |
| CPB | 23,795 | 97.3% |
| SCLX | 23,064 | NEW |
| IMCR | 22,417 | 210.3% |
| WDAY | 22,372 | 198.5% |
Top Reduces (Value $000, Stocks/ETFs)
| Deciphera Pharmaceuticals, Inc. | -92,807 | -100.0% |
| KO | -35,148 | -76.3% |
| POST | -26,796 | -100.0% |
| NOMD | -26,436 | -100.0% |
| SYY | -25,541 | -100.0% |
| RIGL | -22,733 | -100.0% |
| BIIB | -21,574 | -100.0% |
| Shockwave Medical, Inc. | -21,547 | -100.0% |
| NEVRO CORP | -21,413 | -40.9% |
| ARGX | -17,934 | -17.3% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
4,125,274
(51.9% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|